Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-05-01
2007-05-01
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S254100, C424S253100, C424S234100, C424S236100, C514S002600, C530S300000, C530S350000
Reexamination Certificate
active
10334796
ABSTRACT:
The invention relates to a method of immunizing a mammal against infection by a firstBordetellaspecies. The method comprises administering to the mammal a preparation comprising a portion of the amino acid sequence of mature adenylate cyclase of a secondBordetellaspecies. The invention also relates to vaccine preparations comprising a portion of the amino acid sequence of mature adenylate cyclase fromBordetellaspecies.
REFERENCES:
patent: 4652521 (1987-03-01), Confer et al.
patent: 5095094 (1992-03-01), Brezin et al.
patent: 5183745 (1993-02-01), Danchin et al.
patent: 5237052 (1993-08-01), Novotny
patent: 5438120 (1995-08-01), Novotny
patent: 5595901 (1997-01-01), Rocancourt et al.
patent: 5648080 (1997-07-01), Novotny
patent: 5786189 (1998-07-01), Locht et al.
patent: 5939064 (1999-08-01), Savelkoul et al.
patent: 5976544 (1999-11-01), Charles et al.
patent: 5985286 (1999-11-01), Gueirard et al.
patent: 6030625 (2000-02-01), Gueirard et al.
patent: 6040427 (2000-03-01), Locht et al.
patent: 6048700 (2000-04-01), Novotny et al.
patent: 6127151 (2000-10-01), Novotny et al.
patent: 6210685 (2001-04-01), Novotny et al.
patent: 6214356 (2001-04-01), Guiso-Maclouf
patent: 6284256 (2001-09-01), Savelkoul et al.
patent: 6309648 (2001-10-01), Betsou et al.
patent: 6372227 (2002-04-01), Garcon et al.
patent: 6387377 (2002-05-01), Gueirard et al.
patent: 6399076 (2002-06-01), Vose et al.
patent: 6964767 (2005-11-01), Guiso-Maclouf et al.
patent: 7070779 (2006-07-01), Boursaux-Eude et al.
patent: 2002/0172691 (2002-11-01), Guiso-Maclouf
patent: 2003/0108572 (2003-06-01), Novotny et al.
patent: 2003/0224003 (2003-12-01), Guiso-Maclouf
patent: 2006/0008474 (2006-01-01), Boursaux-Eude et al.
patent: 0 267 998 (1988-05-01), None
patent: 0 272 174 (1988-06-01), None
patent: 0 301 954 (1989-02-01), None
patent: 0338170 (1989-10-01), None
patent: 1188446 (2002-03-01), None
patent: 2 606 789 (1988-05-01), None
patent: 2 621 597 (1989-04-01), None
patent: WO 9013312 (1990-11-01), None
Musser et al, J. Bacteriology, 1986, 166/1: 230-237.
Watanbe et al, Infection and Immunity, 2003, 71/2: 733-738.
Kourova et al, J. Clinical Microbiology, 2003, 41/8:3706-3711.
Parkhill et al, Nat. Genet., 2003, 35/1:32-40 Abstract Only.
Kawai et al, Scand. J. Infect. Dis., 1996, 28/4:377-381 Abstract Only.
Liese et al, Archives of Disease in Childhood, 2003, 88:684-687 Abstract Only.
Bergfors et al, Int. J. Infect. Dis., 1999 Spring, 3/3:140-146 Abstract Only.
He et al, JAMA, 1998, 280/7:635-637 Abstract Only.
Hozbor et al, Current Microbiology, 1999, 38/5:273-278 Abstract Only.
Parkhill et al, Nature Genetics, Sep. 2003, 35/1:32-40.
Simsova et al, Int. J. Med. Micrbiol, 2004, 293:571-576.
Strobel et al, J. Mol. Biol., 2003, 332:1-7.
Ladant et al, Trends in Microbiology, Apr. 1999, 7/4:172-176.
Vojtova et al, Current Opinion in Microbiology, 2006, 9:69-75.
Ahuja et al, Critical Reviews in Microbiology, 2004, 30:187-196.
Novotny et al., Develop. Biol. Std., vol. 61, pp. 27-41, 1985.
Hewlett et al., Soluble HA from Culture Medium ofBordetella pertussis: Purification and Char., J. of Bact., vol. 724, p. 890-898.
Robinson, A., Vaccine, vol. 3, pp. 11-22, Mar. 1985.
Robinson, A., Infection & Immunity, May 1983, 40(2), pp. 523-528.
Glaser et al., Molecular Microbiology, 2:19-30, 1988.
Guiso et al., Microbiol. Pathogenesis 7:373-380, 1989.
Ladant et al., J. of Biol. Chem. 261:16264-16269, 1986.
Novotny et al., J. of Infec. Disease 164: 114-22, 1991.
Novotny et al., Inf. & Immun. 50:199-206, 1985 (Abstract only).
Basset et al., Infection & Immun., 68/4: 1934-1941, Apr. 2000.
Khelef et al., Infection & Immun., 61/2: 486-490, Feb. 1993.
Mills et al., Infection & Immun., 61/2: 399-410, Feb. 1993.
Mills et al., Infection & Immun., 66/2: 594-602, Feb. 1998.
Kendrick et al., Am. J. Public Health, 37/7: 803-810, Jul. 1947.
Guiso, et al., Proceedings of 6thPertussisMtg., pp. 207-211, 1990.
Brezin, et al., FEMS Microbiology Letters 42: 75-80, 1987.
Romanos, et al., “RecombinantBordetella pertussispertactin (P69) from the yeastPichia pastoris: high-level production and immunological properties,” Vaccine, vol. 9, pp. 901-906, Dec. 1991.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Institut Pasteur
Minnifield Nita
LandOfFree
Use of adenylate cyclase or bacteria producing it as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of adenylate cyclase or bacteria producing it as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of adenylate cyclase or bacteria producing it as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3739338